glp-1 suicidal thoughts Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study GLP-1 receptor agonists and risk
Description
CONCLUSION The benefits of GLP-1 agonists in appropriate patient groups remain significant
applies to the studied product in trial conditions SELECT trial (NEJM): 20% lower risk of major cardiovascular events - applies specifically to FDA-approved Wegovy in patients with established cardiovascular disease and overweight/obesity
It's a pattern you can live with
After you stop Estimated decline once dosing ends, based on half-life
